Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 301–350 of 1,400 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06989112	DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer(DE-01)	recruiting	Phase 3	600	AstraZenecaINDUSTRY	23	Sep 3, 2026	clinicaltrials
NCT07413939	RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive(BREnnA)	recruiting	Phase 2 / Phase 3	650	Hoffmann-La Roche